[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-failure-with-hypoxia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-failure-with-hypoxia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,75,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100624652","screening-for-pulmonary-embolism-using-single-channel-electrocardiogram-100624652",false,"NCT07412418","Screening for Pulmonary Embolism Using Single-channel Electrocardiogram","Screening for Pulmonary Embolism Using Single-channel Electrocardiogram Data Using Machine Learning Models","Inclusion Criteria:\n\n1. A clinical condition requiring exclusion of acute pulmonary embolism;\n2. The presence of written informed consent of the patient to participate in the study;\n3. Age from 18 years old and older\n\nNon-inclusion criteria:\n\n1. Refusal to undergo examination or the inability to reliably verify or exclude the diagnosis of pulmonary embolism;\n2. Treatment, in particular anticoagulant therapy, before recording a single-lead ECG;\n3. Conditions in which recording an ECG in lead I is not possible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs, tremor, etc.);\n4. Refusal to sign written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Poor ECG quality, preventing the necessary analysis of a single-channel ECG;\n2. Incomplete examination, preventing a reliable determination of the presence or absence of pulmonary embolism;\n3. Refusal to further participate in the study.",true,"ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample.\n\nThe study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental).\n\nDuring the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines.\n\nAll patients included in the study will undergo electrocardiogramm (ECG) in standart lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the Remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transformation. The result of this study will be the identification of ECG parameters that will correlate with pulmonary embolism.",[25,26,27],"Pulmonary Embolism (Diagnosis)","Respiratory Failure With Hypoxia","Chronic Obstructive Pulmonary Disease (COPD)",[29,30,31,32,33,34],"Screening","single-channel electrocardiogram","machine learning models","pulmonary embolism","respiratory failure","chronic obstructive pulmonary disease","NOT_YET_RECRUITING","2026-04-30",{"date":38,"type":39},"2026-05-01","ACTUAL",{"date":38,"type":21},{"date":42,"type":21},"2028-07-30",{"name":44,"class":45},"I.M. Sechenov First Moscow State Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100631655","physiological-study-of-high-peep-in-noninvasive-ventilation-100631655","NCT07503509","Physiological Study of High PEEP in Noninvasive Ventilation","A Physiological Study of High PEEP During Noninvasive Ventilation in Patients With Hypoxemic Respiratory Failure","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. PaCO₂ ≤ 50 mmHg\n3. PaO₂\u002FFiO₂ ≤ 300 mmHg\n4. Use of a noninvasive ventilator with esophageal pressure monitoring capability (e.g., Mindray SV70) -\n\nExclusion Criteria:\n\n1. Respiratory failure caused by heart failure, asthma, or acute exacerbation of chronic obstructive pulmonary disease (COPD) (COPD as a comorbidity may be included)\n2. Pneumothorax\n3. Patients who refuse to participate in this trial -","100 Years",{"count":56,"type":21},50,"INTERVENTIONAL",[59],"NA","To investigate the physiological effects of high positive end-expiratory pressure (PEEP) during noninvasive ventilation in patients with hypoxemic respiratory failure, and to elucidate the mechanisms underlying high PEEP-induced improvement in oxygenation.",[26],[63,64,33],"noninvasive ventilation","PEEP","RECRUITING","2026-03-25",{"date":68,"type":39},"2026-03-31",{"date":70,"type":39},"2024-03-26",{"date":72,"type":21},"2026-06-30",{"name":74,"class":45},"Chongqing Medical University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100593536","identifying-the-best-flow-setting-strategy-for-high-flow-nasal-cannula-100593536","NCT07007715","Identifying the Best Flow Setting Strategy for High-Flow Nasal Cannula","Optimizing High-flow Nasal Cannula Settings: Comparing Different Flow Approaches and Exploring Physiological Phenotyping With End-expiratory Lung Volume, Peak Tidal Inspiratory Flow and Oxygen Demand","Inclusion Criteria:\n\n* Intubated and receiving mechanical ventilation for more than 24 hours\n* Ready for planned extubation after passing a spontaneous breathing trial\n* PaO2\u002FFiO2 \\\u003C350 mmHg on the day of extubation\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* On do-not-reintubate code\n* Pregnant women\n* Having tracheostomies\n* Infeasibility of using HFNC\n* Planning to use preventive NIV after extubation by the primary care team\n* Life expectancy less than one month",{"count":83,"type":21},480,[59],"The goal of this randomized trial is to compare four different flow-setting approaches for post-extubation use of high-flow nasal cannula (HFNC). Selecting the appropriate flow rate when initiating HFNC oxygen therapy is both crucial and challenging for clinicians, as the physiological benefits of HFNC depend significantly on the flow rate. To date, there are no guidelines or consensus on flow-rate setting and weaning for HFNC oxygen therapy.\n\nThe investigators hypothesized that physiological marker-guided flow setting using peak tidal inspiratory flow (PTIF) or PaO₂\u002FFiO₂ ratios lead to better extubation outcomes as compared to empirical flow setting of 40 L\u002Fmin or 60 L\u002Fmin.\n\nParticipants will be randomly assigned to one of four study groups with different flow setting strategies summarized as follows: (1) Setting flow at 40 L\u002Fmin, (2) Setting flow at 5 L\u002Fmin above the peak tidal inspiratory flow, up to a maximum of 60 L\u002Fmin. (3) Setting flow according to P\u002FF ratio prior to extubation. Flow will be set at 60, 50 40 L\u002Fmin if P\u002FF ratio \\\u003C250 mmHg, 250-300 mmHg and \\>300 mmHg, respectively. (4) Setting flow at 60 L\u002Fmin.",[87,26],"Extubation Readiness",[89,90,91,92],"flow rate","high flow nasal cannula","peak inspiratory flow","reintubation","2025-06-05",{"date":95,"type":39},"2025-06-06",{"date":93,"type":39},{"date":98,"type":21},"2028-06-30",{"name":100,"class":45},"National Taiwan University Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":57,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":4},"100573465","comparison-between-four-weaning-methods-from-high-velocity-nasal-insufflation-device-in-acute-hypoxemic-respiratory-failure-100573465","NCT06746636","Comparison Between Four Weaning Methods from High-velocity Nasal Insufflation Device in Acute Hypoxemic Respiratory Failure","HVNI","Inclusion Criteria:\n\n* This study will include Patients over 18 years receiving respiratory support through HVNI for acute hypoxemic respiratory failure\n* Those eligible for weaning according to European Respiratory Society weaning criteria\n\nExclusion Criteria:\n\nI. Extensive facial trauma or burn II. Refusal to participate. III. Usual long-term treatment with NIV for chronic disease IV. Tracheotomy or other upper airway disorders","80 Years",{"count":110,"type":21},120,[59],"High-flow nasal oxygen therapy (HFNO) is an innovative high-flow system that allows for delivering up to 60 liters\u002F min of heated and fully humidified gas with a fraction of inspired oxygen (FIO2) ranging between 21% and 100% . High-flow nasal oxygen therapy has become an increasingly popular choice of therapy due to the potential complications of invasive ventilation and the frequent uncomfortable or life-threatening adverse effects that are produced in non-invasive ventilation (NIV) . The HFNO allows the modification of only two variables: the percentage of oxygen being delivered and the rate of gas flow . Numerous well-designed studies have been conducted into the use of the HFNC in the treatment of critically ill patients, and HFNC is now widely used in the treatment of patients with various diagnoses including acute hypoxemic respiratory failure or acute respiratory distress syndrome (ARDS) , and is used in post-extubation treatment, post-cardiothoracic surgery respiratory distress , and respiratory compromise induced by heart failure .\n\nHigh-velocity nasal insufflation (HVNI) is a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than its counterparts using large bore HFNC. HVNI can accomplish a complete purge of extrathoracic dead space and may be able to provide ventilatory support in patients with acute hypercapnic respiratory failure in addition to oxygenation support.\n\nThis study is necessary because, even though studies were being conducted to determine both the optimal technique for HFNO delivery and the clinical setting in which it is most useful, the best strategy for weaning from HVNI remains unknown. It has also not been established at what point a patient should be considered stable enough to attempt for withdrawing the HVNI",[114],"Respiratory Failure with Hypoxia",[106,116,117,118],"HFNC","HFNO","weaning","2024-12-21",{"date":121,"type":39},"2024-12-27",{"date":123,"type":21},"2025-01-01",{"date":38,"type":21},{"name":126,"class":45},"Assiut University"]